TumPF Cancer Research Results

TumPF, Tumor-promoting fibroblasts: Click to Expand ⟱
Source: HalifaxProj(deactivate)
Type:
Tumor-promoting fibroblasts, often referred to as cancer-associated fibroblasts (CAFs), play a significant role in the tumor microenvironment and contribute to cancer progression.
CAFs are derived from various sources, including resident fibroblasts, mesenchymal stem cells, and even epithelial cells through a process called epithelial-to-mesenchymal transition (EMT). They exhibit distinct characteristics compared to normal fibroblasts, including altered gene expression and increased secretion of growth factors and cytokines.


Scientific Papers found: Click to Expand⟱
7185- CHA,    Chaetocin-induced ROS-mediated apoptosis involves ATM–YAP1 axis and JNK-dependent inhibition of glucose metabolism
- vitro+vivo, GBM, A172 - in-vitro, GBM, T98G - in-vitro, GBM, U87MG
HMTs↓, Chaetocin, a histone methyltransferase inhibitor, is known to induce ROS generation.
ROS↑,
p‑ATM↑, Chaetocin-treated tumors exhibited heightened ROS, pATM, YAP1 and pJNK levels
YAP/TEAD↑, An increase in YAP1 level and decrease in YAP1 phosphorylation was observed upon Chaetocin treatment
p‑JNK↑,
TumPF↓, Chaetocin inhibits glioma cell proliferation
SUV39H↓, Chaetocin, an inhibitor of lysine-specific histone methyltransferase SUV39H1
TrxR↓, Chaetocin reduces thioredoxin reductase activity in a dose-dependent manner.
Casp3↑, Treatment with Chaetocin resulted in ∼3–5-fold increase in caspase-3 activity
Trx1↓, Chaetocin decreases the expression of TRX-1 in glioma cells
H3↓, Chaetocin-mediated inhibition of histone H3 methylation is ROS dependent
lactateProd↓, Chaetocin decreases lactate levels, ATP production and glucose uptake in a ROS- and JNK-dependent manner
ATP↓,
GlucoseCon↓,
TumCG↓, Chaetocin inhibits growth of tumor xenograft in nude mice
Dose↝, 10 animals each and were administered either with vehicle or Chaetocin (0.5 mg/kg body weight), intraperitoneally on alternate days for 25 days.

5099- JG,    Juglone induces ferroptosis in glioblastoma cells by inhibiting the Nrf2-GPX4 axis through the phosphorylation of p38MAPK
- vitro+vivo, GBM, LN229 - vitro+vivo, GBM, T98G
Ferroptosis↑, Juglone mainly causes cell death by inducing ferroptosis
p‑MAPK↑, juglone can significantly activate the phosphorylation of p38MAPK
NRF2↓, juglone induces the ferroptosis of GBM by activating the phosphorylation of p38MAPK and negatively regulating the Nrf2-GPX4 signaling pathway.
GPx4↓,
TumPF↓, Juglone significantly inhibits the proliferation of GBM cells and induces cell apoptosis
Apoptosis↑,
ROS↑, Juglone can dose-dependently enhance the accumulation of ROS in GBM cells
GSH↓, juglone can reduce the content of GSH
lipid-P↑, lipid peroxidation
Ki-67↓, The results show that juglone significantly inhibits the expression of Ki67, GPX4, and Nrf2
TumCG↓, juglone inhibits tumor growth in vivo by inducing ferroptosis.


Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0)

SUV39H↓, 1,  

Redox & Oxidative Stress(tgid=1)

Ferroptosis↑, 1,   GPx4↓, 1,   GSH↓, 1,   lipid-P↑, 1,   NRF2↓, 1,   ROS↑, 2,   Trx1↓, 1,   TrxR↓, 1,  

Mitochondria & Bioenergetics(tgid=3)

ATP↓, 1,  

Core Metabolism/Glycolysis(tgid=4)

GlucoseCon↓, 1,   lactateProd↓, 1,  

Cell Death(tgid=5)

Apoptosis↑, 1,   Casp3↑, 1,   Ferroptosis↑, 1,   p‑JNK↑, 1,   p‑MAPK↑, 1,   YAP/TEAD↑, 1,  

Transcription & Epigenetics(tgid=7)

H3↓, 1,  

DNA Damage & Repair(tgid=10)

p‑ATM↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12)

HMTs↓, 1,   TumCG↓, 2,  

Migration(tgid=13)

Ki-67↓, 1,   TumPF↓, 2,  

Drug Metabolism & Resistance(tgid=21)

Dose↝, 1,  

Clinical Biomarkers(tgid=22)

Ki-67↓, 1,  
Total Targets: 26

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: TumPF, Tumor-promoting fibroblasts
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:329  State#:%  Dir#:1
wNotes=on sortOrder:rid,rpid

 

Home Page